Stephens Consulting, LLC Biotechnology

Stephens Consulting, LLC

$399 Billion
Q1 2025

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade	Trade History
BCRX Biocryst Pharmaceuticals Inc	$2.07B	$375,000 0.0% of portfolio	50	Q1 2025 New
XNCR Xencor Inc	$570M	$373,000 0.0% of portfolio	35	Q1 2025 New
ARDX Ardelyx, Inc.	$612M	$369,000 0.0% of portfolio	75	Q1 2025 New
LQDA Liquidia Corp	$1.18B	$369,000 0.0% of portfolio	25	Q1 2025 New
SNDX Syndax Pharmaceuticals Inc	$631M	$369,000 0.0% of portfolio	30	Q1 2025 New
DYN Dyne Therapeutics, Inc.	$737M	$367,000 0.0% of portfolio	35	Q1 2025 New
IOVA Iovance Biotherapeutics, Inc.	$349M	$367,000 0.0% of portfolio	110	Q1 2025 New
OCUL Ocular Therapeutix, Inc	$664M	$367,000 0.0% of portfolio	50	Q1 2025 New
GERN Geron Corp	$589M	$366,000 0.0% of portfolio	230	Q1 2025 New
ETNB 89bio, Inc.	$473M	$364,000 0.0% of portfolio	50	Q1 2025 New
CLDX Celldex Therapeutics, Inc.	$913M	$363,000 0.0% of portfolio	20	Q1 2025 New
AUPH Aurinia Pharmaceuticals Inc.	$1.16B	$362,000 0.0% of portfolio	45	Q1 2025 New
VERA Vera Therapeutics, Inc.	$567M	$361,000 0.0% of portfolio	15	Q1 2025 New
COGT Cogent Biosciences, Inc.	$402M	$360,000 0.0% of portfolio	60	Q1 2025 New
TVTX Travere Therapeutics, Inc.	$957M	$359,000 0.0% of portfolio	20	Q1 2025 New
NRIX Nurix Therapeutics, Inc.	$589M	$357,000 0.0% of portfolio	30	Q1 2025 New
VIR Vir Biotechnology, Inc.	$720M	$357,000 0.0% of portfolio	55	Q1 2025 New
XERS Xeris Biopharma Holdings, Inc.	$617M	$357,000 0.0% of portfolio	65	Q1 2025 New
KALV Kal Vista Pharmaceuticals, Inc.	$345M	$347,000 0.0% of portfolio	30	Q1 2025 New
AVXL Anavex Life Sciences Corp.	$606M	$344,000 0.0% of portfolio	40	Q1 2025 New
IMVT Immunovant, Inc.	$3.55B	$342,000 0.0% of portfolio	20	Q1 2025 New
REPL Replimune Group, Inc.	$481M	$342,000 0.0% of portfolio	35	Q1 2025 New
CRSP Crispr Therapeutics Ag	$3.35B	$341,000 0.0% of portfolio	10	Q3 2024 New
IMNM Immunome Inc.	$112M	$337,000 0.0% of portfolio	50	Q1 2025 New
VRDN Viridian Therapeutics, Inc.\De	$579M	$337,000 0.0% of portfolio	25	Q1 2025 New
ADPT Adaptive Biotechnologies Corp	$1.41B	$335,000 0.0% of portfolio	45	Q1 2025 New
RCKT Rocket Pharmaceuticals, Inc.	$210M	$334,000 0.0% of portfolio	50	Q1 2025 New
HRMY Harmony Biosciences Holdings, Inc.	$2.1B	$332,000 0.0% of portfolio	10	Q1 2025 New
IDYA Ideaya Biosciences, Inc.	$1.01B	$328,000 0.0% of portfolio	20	Q1 2025 New
ALT Altimmune, Inc.	$268M	$325,000 0.0% of portfolio	65	Q1 2025 New
WVE Wave Life Sciences Ltd.	$606M	$324,000 0.0% of portfolio	40	Q1 2025 New
NVAX Novavax Inc	$580M	$321,000 0.0% of portfolio	50	Q1 2025 New
NTLA Intellia Therapeutics, Inc.	$629M	$320,000 0.0% of portfolio	45	Q1 2025 New
VERV Verve Therapeutics, Inc.	$343M	$320,000 0.0% of portfolio	70	Q1 2025 New
ARVN Arvinas, Inc.	$417M	$316,000 0.0% of portfolio	45	Q1 2025 New

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Stephens Consulting, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Stephens Consulting, LLC with notifications on news.